ATOH1 and medulloblastoma: In contrast, the transformation of committed EGL progenitors postnatally (Fsmo;Atoh1-CreER) resulted in adult SHH medulloblastomas that contain SD-CSCs (18); these tumors are sensitive to SMOi treatment and require acquired mutations for resistance to emerge, which may explain the higher ORR in the sonidegib trial.